Evaluating Healthcare Branding Agencies: Key Questions

The Four Determinants That Actually Move Admissions

The systematic review of hospital brand equity identifies four determinants that consistently predict how patients choose and re-choose a facility: perceived service quality, hospital image, patient satisfaction, and loyalty ³. Those four variables are the reason brand equity translates into census. When patients weigh a treatment center against alternatives, they are not comparing color palettes or tagline elegance; they are drawing on impressions of clinical competence, institutional character, prior experience, and the willingness to return or refer. The same review notes that strong brand equity strengthens patient trust and raises perceived prestige, which is the pathway from brand work to admissions volume ³.

For evaluation purposes, each determinant maps to a distinct agency capability. Perceived service quality requires messaging that reflects actual clinical protocols, staffing ratios, and modalities—content strategy work grounded in program specifics, not stock language about “personalized care.” Hospital image requires positioning and visual identity discipline that holds together across intake calls, alumni communications, and third-party review platforms. Patient satisfaction requires the agency to coordinate with clinical and operations leadership so that the brand promise does not outrun the lived experience. Loyalty requires post-discharge communication frameworks and alumni programs that respect HIPAA constraints on outreach ⁵.

Brand managers presenting an evaluation rubric to executives can trace every scoring criterion back to one of these four determinants. If a proposed criterion does not connect to service quality, image, satisfaction, or loyalty, it is likely measuring agency output rather than patient-choice mechanics.

Testing Whether an Agency Can Influence Those Drivers

A capable agency should be able to explain, in operational terms, how a proposed engagement moves at least one of the four determinants. Vague answers about “elevating the brand” or “telling your story” do not survive that test. Brand managers should ask the agency to walk through a prior engagement and identify which determinant the work targeted, what evidence was used to measure movement, and where the work fell short.

Perceived service quality is the easiest determinant to probe during a pitch. Ask the agency how it would substantiate a claim that a facility offers superior care. If the answer references outcomes statistics, the FTC standard of competent and reliable scientific evidence applies, and the agency should say so without prompting ⁴. Hospital image is harder to test but reveals itself in how the agency handles reputational risk—review response protocols, crisis messaging, and the boundary between promotional content and the truthful, non-misleading standard that peer-reviewed ethics work treats as the floor for medical promotion ².

Patient satisfaction and loyalty require the agency to interact with data. Ask how it would segment alumni communications without triggering HIPAA’s marketing authorization requirement, which applies whenever protected health information is used to encourage recipients to purchase or use a service ⁵. An agency that cannot articulate that boundary is not equipped to build loyalty programs. The screening question is simple: can the agency name the determinant, the mechanism, and the evidentiary or consent burden without a lawyer in the room?

HIPAA Marketing Definition, Authorization, and PHI in Agency Workflows

HIPAA defines marketing as a communication about a product or service that encourages recipients to purchase or use it, and requires written authorization before protected health information is used or disclosed for that purpose, with limited exceptions ⁵. That definition is broader than most agency pitches assume. When a proposed campaign draws on admission records to segment past patients, when an alumni newsletter promotes a new IOP track, or when a retargeting audience is built from anyone whose data touched an intake form, PHI is in play and authorization becomes the operative question.

Brand managers should ask any agency to walk through, in writing, how PHI enters and exits its workflows. The answers should name specific systems: which CRM holds patient identifiers, who has access, how audiences are constructed for paid media, and where consent language for authorization lives in the intake flow. Agencies that describe segmentation using clinical data without addressing authorization are operating outside the rule.

The remuneration provision closes another gap. HIPAA treats a disclosure of PHI made in exchange for direct or indirect payment to another entity that will use it to encourage recipients to purchase a service as marketing with no exception—authorization is required in every case ⁶. That language matters when agencies propose data-sharing arrangements with lead aggregators, call centers, or third-party platforms. If the agency cannot describe the authorization mechanics for those flows, the arrangement is not defensible, regardless of the volume it promises to deliver.

FTC Substantiation, Endorsement Disclosures, and Implied Claims

The FTC’s Health Products Compliance Guidance sets two baseline requirements: advertising must be truthful and not misleading, and advertisers must hold competent and reliable scientific evidence for every objective product claim before dissemination ⁴. “Objective” is where agencies stumble. A claim that a program has a specific completion rate, that a therapy resolves a specific symptom, or that outcomes exceed a national average is an objective claim requiring substantiation. Aspirational language framed as fact carries the same burden.

Implied claims trigger the standard as well. A landing page that pairs a smiling alumni photo with the phrase “a new life” implies an outcome even if no percentage appears on screen. An agency should demonstrate that it screens copy for implied claims and maintains a substantiation file mapped to each claim in a live campaign. The absence of that file is the flag.

Endorsements and testimonials carry their own layer. The FTC requires clear and conspicuous disclosure of any material connection between an endorser and the advertiser, and advertisers are liable for misleading use of testimonials ⁴. Compensated alumni, staff members portrayed as third parties, and influencers with fee arrangements all fall inside that rule. Ask the agency to show its endorsement disclosure template, its process for verifying that a testimonial reflects a typical result, and its documentation of the endorser’s relationship. If those artifacts do not exist, endorsement work should be scoped out of the engagement.

SAMHSA, AMA, and Professional Ethics for Clinician-Fronted Campaigns

SAMHSA’s 2024 contingency management advisory draws a firm line: CM incentives must not be used to recruit patients into treatment or to advertise a practice ⁷. Agencies unfamiliar with behavioral health sometimes propose gift cards, milestone rewards, or referral bonuses as engagement mechanics. Applied to SUD populations, those tactics collide with the advisory’s coercion concerns and turn a clinical tool into a marketing liability.

The AMA’s advertising ethics opinion requires that physician communications be explicitly and implicitly truthful, and that a reasonable evidentiary basis exist for claims before they appear in advertising ⁸. That standard extends to any campaign that puts a clinician on camera, in a byline, or in a testimonial frame. The AMA’s direct-to-consumer opinion flags the risk of unrealistic expectations and compromised patient-physician relationships when persuasive messaging leads the creative ⁹, and its social media guidance directs clinicians to maintain patient-physician boundaries in online promotional contexts ¹⁰.

When agencies propose clinician-fronted content, brand managers should require full disclosure of financial arrangements and an evidence-based review of any product or program claim the clinician will make—the same standard the AMA has pressed for in resolutions on paid endorsements ¹¹. Agencies that treat clinician talent as brand ambassadors without addressing disclosure and evidentiary basis are creating exposure the medical staff will inherit.

The Monument Case: What FTC Enforcement Actually Looks Like

In April 2024, the FTC settled a case against Monument, an alcohol addiction treatment firm, resulting in an order that bans the company from disclosing health information for advertising and requires affirmative consent before sharing health information with third parties for any other purpose ¹². The order is the concrete answer to any executive who asks what regulatory risk actually looks like in this category.

The pattern that led to enforcement is familiar in agency pitches: pixels and tags on pages that capture health-related activity, audience objects synced to ad platforms, retargeting audiences assembled from users whose visits reveal sensitive conditions. Brand managers evaluating an agency should ask whether any prior client has removed a tracking pixel at counsel’s request, how the agency handles conversion tracking on pages that reveal diagnosis or treatment interest, and what its default position is when a platform’s targeting features require sharing health-adjacent data. An agency that treats the Monument outcome as a niche cautionary tale rather than a live operating constraint is not ready to run behavioral health accounts.

Texas HSC Chapter 164 as a Benchmark for State Exposure

Texas Health and Safety Code Chapter 164 is worth reading not because every operator has a Texas facility, but because it shows how a state legislature translates general concerns about misleading treatment marketing into specific statutory prohibitions. The chapter’s stated purpose is to safeguard the public against fraud, deceit, and misleading marketing practices by prohibiting or restricting practices that have injured the public in connection with the marketing of mental health services and the admission of patients ¹. Its definition of advertising is deliberately broad, reaching internet solicitations and media placements that agencies often treat as generic performance channels.

If You Manage Multiple Licensed Facilities Across States

This subsection shifts the reader from single-facility brand management to portfolio operators—health systems, multi-facility treatment groups, and behavioral health platforms running licensed facilities across several states. The evaluation framework does not change in principle, but three variables scale nonlinearly and should appear on the scorecard.

The first is state-statute exposure count. Each licensed jurisdiction adds a statutory surface the agency must map. A brand manager overseeing five states should require a written inventory identifying each state’s marketing statute, its definition of advertising, and its restrictions on referral, admission, and testimonial practices, using Chapter 164 as the reference format ¹. Agencies unwilling to produce that inventory during scoping will not produce it under deadline pressure.

The second is PHI-handling surface area. Every additional facility multiplies the number of intake systems, CRMs, and consent flows the agency touches. HIPAA’s authorization requirement applies at each entry point, and the remuneration provision has no exceptions when PHI moves to a third party for marketing purposes ⁶. A portfolio-level data-flow map, not a facility-by-facility patchwork, should be a deliverable.

The third is endorsement inventory. Alumni testimonials, clinician bylines, and influencer relationships accumulate across a portfolio, and each carries its own disclosure and substantiation obligations under FTC guidance ⁴. A central registry, not distributed marketing files, is the operating standard.